week 7 drugs

HideShow resource information
  • Created by: hadar
  • Created on: 16-04-16 15:46
Factor VIII concentrate- mechanism of action
from the complex to interact with factor IXa in the coagulation cascade
1 of 8
Factor VIII concentrate- therapeutic effect
being able to form complex with factor IX means that it can activate factor X and the common pathway of the coagulation cascade
2 of 8
Desmopressin- mechanism of action
Agonist activity at V2 receptors on vascular endothelial cells leads to a rise in intracellular concentrations of cyclic adenosine monophosphate, which in turn induces exocytosis of VWF from its storage sites
3 of 8
Desmopressin- therapeutic effect
Increasing VWF stabilised factor VIII and also promotes platelet aggregation
4 of 8
Tranexamic acid - mechanism of action
competitively inhibits activation of plasminogen (via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin also directly inhibits plasmin activity,
5 of 8
Tranexamic acid- therapeutic effect
competitively inhibits the activation of plasminogen to plasmin. and therefore less of the fibrin matrix is degraded
6 of 8
Hydroxyurea/ Hydroxycarbamide- mechanism of action
3 mechanisms : - ribonuclease reductase inhibitor -NO pathway -RNA inhibitor
7 of 8
Hydroxyurea/ Hydroxycarbamide- therapeutic effect
increases the concentration of fetal hemoglobin.
8 of 8

Other cards in this set

Card 2

Front

being able to form complex with factor IX means that it can activate factor X and the common pathway of the coagulation cascade

Back

Factor VIII concentrate- therapeutic effect

Card 3

Front

Agonist activity at V2 receptors on vascular endothelial cells leads to a rise in intracellular concentrations of cyclic adenosine monophosphate, which in turn induces exocytosis of VWF from its storage sites

Back

Preview of the back of card 3

Card 4

Front

Increasing VWF stabilised factor VIII and also promotes platelet aggregation

Back

Preview of the back of card 4

Card 5

Front

competitively inhibits activation of plasminogen (via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin also directly inhibits plasmin activity,

Back

Preview of the back of card 5
View more cards

Comments

No comments have yet been made

Similar All resources:

See all All resources »See all pharma resources »